Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Hassiba El Bouazzati"'
Autor:
Sylvie Galiègue‐Zouitina, Qiangwei Fu, Céline Carton‐Latreche, Nicolas Poret, Meyling Cheok, Frédéric Leprêtre, Martin Figeac, Bruno Quesnel, Hassiba El Bouazzati, Carl S Shelley
Publikováno v:
eJHaem, Vol 2, Iss 2, Pp 196-210 (2021)
Abstract RhoH is an unusual member of the Rho family of small GTP‐binding proteins in that it lacks GTPase activity. Since the RhoH protein is constantly bound by GTP, it is constitutively active and controlled predominantly by changes in quantitat
Externí odkaz:
https://doaj.org/article/d9fa8181839449a0b718389d9f9b0f02
Autor:
Romain Regnault, Frédérique Klupsch, Hassiba El-Bouazzati, Romain Magnez, Raphaël Le Biannic, Natascha Leleu-Chavain, Hania Ahouari, Hervé Vezin, Régis Millet, Jean-François Goossens, Xavier Thuru, Christian Bailly
Publikováno v:
Molecules; Volume 28; Issue 8; Pages: 3491
Molecules
Molecules, 2023, 28 (8), pp.3491. ⟨10.3390/molecules28083491⟩
Molecules
Molecules, 2023, 28 (8), pp.3491. ⟨10.3390/molecules28083491⟩
International audience; Orally-active anticancer small molecules targeting the PD-1/PD-L1 immune checkpoint are actively searched. Phenyl-pyrazolone derivatives with a high affinity for PD-L1 have been designed and characterized. In addition, the phe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b68971e1942055b141e85a5994312130
http://hdl.handle.net/20.500.12210/85126
http://hdl.handle.net/20.500.12210/85126
Autor:
Xavier Thuru, Romain Magnez, Hassiba El-Bouazzati, Gérard Vergoten, Bruno Quesnel, Christian Bailly
Publikováno v:
Cancers
Cancers, 2022, 14 (14), pp.3368. ⟨10.3390/cancers14143368⟩
Cancers, 2022, 14 (14), pp.3368. ⟨10.3390/cancers14143368⟩
International audience; Monoclonal antibodies targeting the PD-1/PD-L1 immune checkpoint have considerably improved the treatment of some cancers, but novel drugs, new combinations, and treatment modalities are needed to reinvigorate immunosurveillan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cb9c360a57f65a91ac91882f77933f9
https://hal.science/hal-03857329
https://hal.science/hal-03857329
Autor:
Raphaël Le Biannic, Romain Magnez, Frédérique Klupsch, Natascha Leleu-Chavain, Bryan Thiroux, Morgane Tardy, Hassiba El Bouazzati, Xavier Dezitter, Nicolas Renault, Gérard Vergoten, Christian Bailly, Bruno Quesnel, Xavier Thuru, Régis Millet
Publikováno v:
European Journal of Medicinal Chemistry
European Journal of Medicinal Chemistry, 2022, 236, pp.114343. ⟨10.1016/j.ejmech.2022.114343⟩
European Journal of Medicinal Chemistry, 2022, 236, pp.114343. ⟨10.1016/j.ejmech.2022.114343⟩
Immuno-therapy has become a leading strategy to fight cancer. Over the past few years, immuno-therapies using checkpoint inhibitor monoclonal antibodies (mAbs) against programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) have demo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ab833e33558bab0547d52ecf4719d73
https://hal.science/hal-03641793
https://hal.science/hal-03641793
Autor:
Nicolas Poret, Qiangwei Fu, Martin Figeac, Carl Simon Shelley, Sylvie Galiègue-Zouitina, Bruno Quesnel, Meyling Cheok, Céline Carton‐Latreche, Frédéric Leprêtre, Hassiba El Bouazzati
Publikováno v:
eJHaem. 2:196-210
Autor:
Yasmine Touil, Céline Latreche‐Carton, Hassiba El Bouazzati, Anne‐Lucie Nugues, Nathalie Jouy, Xavier Thuru, William Laine, Frederic Lepretre, Martin Figeac, Meryem Tardivel, Jérôme Kluza, Thierry Idziorek, Bruno Quesnel
Publikováno v:
Journal of Cellular Biochemistry
Journal of Cellular Biochemistry, 2022, 123 (3), pp.543-556. ⟨10.1002/jcb.30198⟩
Journal of Cellular Biochemistry, 2022, 123 (3), pp.543-556. ⟨10.1002/jcb.30198⟩
International audience; Receptor-interacting protein kinase 3 (RIPK3) can induce necroptosis, apoptosis, or cell proliferation and is silenced in several hematological malignancies. We previously reported that RIPK3 activity independent of its kinase
Autor:
Hassiba El Bouazzati, Frederique Klupsch, Morgane Tardy, Natascha Leleu-Chavain, Romain Magnez, Bruno Quesnel, Christian Bailly, Xavier Thuru, Régis Millet
Publikováno v:
Cancer Research. 80:5340-5340
Immuno-therapy has become a leading strategy to fight cancer. Over the past few years, immuno-therapies using checkpoint inhibitor monoclonal antibodies (mAbs) against programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) have demo
Autor:
Bruno Quesnel, Isabelle Briche, Jerome Kluza, Xavier Thuru, Sylvie Aliegue-Zouitina, Julie Berthe, Hassiba El Bouazzati
Publikováno v:
Cancer Research. 78:384-384
When evolving to a neoplastic state, normal cells acquire many characteristics; indeed, tumor cells follow abnormal metabolic pathways and exhibit the ability to avoid immune destruction, partly by exploiting immune checkpoints. Many of these are cur